Can we afford to treat hyperlipidaemia as we should strategies for rational treatment

Atherosclerosis

Volumn 139, Issue SUPPL. 1, 1998, Pages 1-5

  Durrington, P N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Coronary heart disease; Hyperlipidaemia; Lipid lowering drug therapy

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; EUROPE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; UNITED KINGDOM; UNITED STATES;

EID: 0031668841     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0021-9150(98)00187-7     Document Type: Conference Paper

References (25)

1. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994;308:373-9.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994;308:367-73.
3. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefits. A new look at old data. Circulation 1995;91:2274-82.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Survival Study. Lancet 1994;344:1383-1389.
5. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71.
6. Haq IU, Ramsay LE, Pickin JN, Yeo WW, Jackson PR, Payne JN. Lipid lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996;91:399-413.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 1995;333:1301-1307.
9. NHS Executive. Standing Medical Advisory Committee Statement on the use of statins Executive Letter EL(97)41. Wetherby: Department of Health, 1997.
10. Pyorala K, de Backer G, Graham I, Poole-Wilson P, Wood D. On behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendation of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
11. West of Scotland Coronary Prevention Group, West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996;348:1339-1343.
12. Aspire Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Principal results. Heart 1996;75:334-342.
13. La Rosa JC, Pearson TA. Cholesterol screening guidelines. Consensus evidence, and the departure from common sense. Circulation 1997;95:1651-3.
14. Marques-Vidal P, Evans AE, Cambou J-P, Arveiler D, Luc G, Bingham A, et al. Awareness and control of hypertension and hypercholesterolaemia in France and Northern Ireland. Q J Med 1997;90:341-5.
15. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) J Am Med Assoc 1993; 269:3015-3023.
16. Ramsay LE, Haq IV, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348:387-8.
17. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990;121:293-8.
18. Assmann G, Schulte H, Funke H, von Eckardstein A, Seedorf U. The Prospective Cardiovascular Munster (PROCAM) study: identification of high-risk individuals and the role of high-density lipoprotein. In: Miller NE, editor. High Density Lipoproteins, Reverse Cholesterol Transport, and Coronary Heart Disease. Amsterdam: Exerpta Medica, 1989:46-59.
19. Schulte H, Assmann G. CHD risk equations, obtained from the Framingham Heart Study, applied to the PROCAM Study. Cardiovascular Risk Factors 1991;1:126-33.
20. Durrington PN, Prais H, Bhatnaga D, France M, Crowley V, Khan J, Morgan J. Indications for cholesterol-lowering medication: outcome of different methods for risk assessment. Lancet 1998, in press.
21. Bush TL, Reidel D. Screening for total cholesterol: do the National Cholesterol Screening Program's recommendations detect individuals at high risk of coronary heart disease? Circulation 1991;83:1287-93.
22. McIsaac WJ, Naylor D, Basinski A. Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines. J Gen Intern Med 1991;6:518-23.
23. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. Br Med J 1995;274:801-6.
24. Durrington PN. Normal Serum Lipid and Lipoprotein Concentrations. Ch. 4 in Hyperlipidaemia, Diagnosis and Management, 2nd ed. Oxford: Butterworth Heinemann, 1995:72-103.
25. Mann JI, Crooke M, Fear H, et al. Guidelines for detection and management of dyslipidaemia. New Zealand Med J 1993;106:133-42.